ADUHELM
Clinical safety rating
cautionComprehensive clinical and safety monograph for ADUHELM (ADUHELM).
Comprehensive clinical and safety monograph for ADUHELM (ADUHELM).
Treatment of Alzheimer's disease (FDA approved for patients with mild cognitive impairment or mild dementia stage of disease)
Aducanumab is a human monoclonal antibody that selectively binds to aggregated soluble and insoluble forms of amyloid beta, thereby reducing amyloid plaque deposition in the brain.
| Metabolism | Aducanumab is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via catabolic pathways, similar to endogenous IgG. No specific cytochrome P450 enzymes are involved. |
| Excretion | ADUHELM is eliminated primarily via catabolism into small peptides and amino acids. No renal or biliary excretion of intact monoclonal antibody is expected. Clearance is via the reticuloendothelial system; approximately 97% is metabolized, with <3% excreted as intact antibody in urine. |
| Half-life | Terminal elimination half-life is approximately 26 days (range 19–34 days), supporting monthly intravenous dosing. The long half-life reflects the slow clearance of IgG1 monoclonal antibodies. |
| Protein binding | Approximately 99% bound, primarily to endogenous IgG (via FcRn binding) and other plasma proteins; specific binding proteins include FcRn. |
| Volume of Distribution | Volume of distribution is approximately 6.8 L (central compartment), equivalent to plasma volume; does not distribute extensively into tissues due to large molecular size. In L/kg: ~0.1 L/kg for a 70 kg patient. |
| Bioavailability | Intravenous administration results in 100% bioavailability. No subcutaneous or oral formulation is available; thus no bioavailability for other routes. |
| Onset of Action | Subcutaneous administration not applicable; intravenous infusion: clinical effects on amyloid plaque reduction are observed as early as 6 months, but cognitive benefit may take 12–18 months. |
| Duration of Action | After a single IV infusion, drug levels persist for weeks; weekly dosing maintains steady state. Clinical effect duration is continuous with ongoing treatment; effects wane over months after discontinuation. |
| Molecular Weight | 145000 |
10 mg/kg intravenous infusion over approximately one hour, once every four weeks. Dosing initiation requires a titration schedule: first three doses at 1 mg/kg, fourth dose at 3 mg/kg, fifth dose at 6 mg/kg, and subsequent doses at 10 mg/kg.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (eGFR <30 mL/min/1.73 m²) or end-stage renal disease. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. |
| Pediatric use | Safety and efficacy have not been established in pediatric patients. No recommended dosing available. |
| Geriatric use | No specific dose adjustment recommended for elderly patients. Clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy observed. |
| 1st trimester | No human data; based on animal studies, IgG antibodies cross the placenta in the first trimester. Potential for fetal harm is unknown but cannot be ruled out. |
| 2nd trimester | IgG antibodies actively cross the placenta during second trimester; no human data available. Consider risk-benefit. |
| 3rd trimester | IgG antibodies are actively transported across placenta in third trimester; may reach fetal circulation. No human data. |
Clinical note
Comprehensive clinical and safety monograph for ADUHELM (ADUHELM).
| Placental transfer | IgG antibodies are known to cross the placenta, especially in the second and third trimesters. Aducanumab is a human IgG1 monoclonal antibody and is expected to cross the placenta. The degree of transfer is likely similar to other IgG antibodies. |
| Breastfeeding | It is unknown whether aducanumab is excreted in human milk. IgG antibodies are present in human milk, but systemic absorption in the infant is limited. Consider developmental and health benefits of breastfeeding along with maternal need for therapy and potential adverse effects on the breastfed infant. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Based on mechanism of action (anti-amyloid beta monoclonal antibody), potential for fetal harm is unknown. No animal reproductive studies available. Use only if benefit outweighs potential risk. |
| Fetal Monitoring | Monitor for infusion reactions (hypotension, hypoxia, dyspnea) during administration. Serial clinical assessments for ARIA (amyloid-related imaging abnormalities) via MRI as per standard monitoring. No specific fetal monitoring required; consider ultrasound if clinical concern. |
| Fertility Effects | No data on effects of aducanumab on human fertility. Animal studies not available; no known impact on fertility based on mechanism. |
■ FDA Black Box Warning
WARNING: AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA). Aducanumab can cause ARIA, including ARIA-E (edema/effusion) and ARIA-H (hemorrhage/hemosiderin deposition), which can be serious and life-threatening. ARIA generally occurs within the first 8 doses. Monitoring with MRI is required prior to and during treatment.
| Serious Effects |
Hypersensitivity to aducanumab or any excipientsAmyloid-related imaging abnormalities (ARIA) with severe symptoms
| Precautions | Amyloid-related imaging abnormalities (ARIA), including ARIA-E and ARIA-H, Hypersensitivity reactions including angioedema and urticaria, Risk of seizures (reported in clinical trials), Concomitant use of antithrombotic medications may increase risk of intracranial hemorrhage |
| Food/Dietary | No specific food interactions reported. Patients should maintain a balanced diet as part of overall health management. Avoid grapefruit juice if taking other medications metabolized by CYP3A4, though aducanumab is not metabolized by CYP enzymes. |
| Clinical Pearls | ADUHELM (aducanumab-avwa) is a monoclonal antibody targeting aggregated forms of beta-amyloid. It is indicated for Alzheimer disease. Confirmation of amyloid beta pathology via PET or CSF is required before initiation. Titration over 6-8 months is mandatory to reduce risk of amyloid-related imaging abnormalities (ARIA). Monitor for ARIA with MRI prior to the 7th and 12th infusions; suspend dosing if ARIA is detected. Adverse effects include ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition). Coadministration with anticoagulants may increase risk of ARIA-H. Assess for hypersensitivity reactions. No specific reversal agent is available. |
| Patient Advice | This drug is for patients with mild cognitive impairment or mild Alzheimer disease confirmed by amyloid PET or CSF testing. · Treatment requires intravenous infusion every 4 weeks, with dose titration over at least 6 months. · MRI scans are needed before and during treatment to monitor for brain swelling or small bleeds (ARIA). · Tell your doctor immediately if you experience headache, confusion, dizziness, vision changes, nausea, or seizures. · Avoid blood thinners like warfarin, apixaban, or rivaroxaban unless prescribed; they may increase bleeding risk. · Do not drive or operate heavy machinery if you experience dizziness or visual disturbances. · Report any signs of allergic reaction such as rash, itching, or difficulty breathing. · Store vials in refrigerator and protect from light; do not freeze or shake. |
Loading safety data…